Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BIIL 284 BS Boli vs Tablet C in Healthy Volunteers
NCT02265640Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2000
- Primary completion
- Dec 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of amelubant in rheumatoid arthritis (RA) and cystic fibrosis (CF) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Plasma levels of BIIL 315 ZW up to 72 hours, Area under the concentration-time curve from 0 extrapolated to infinity up to 72 hours and 1 more. Started Oct 2000; status: completed.
02
Drugs
amelubant
03
Conditions
rheumatoid arthritis (RA)cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02265640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265640.